We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
Read MoreHide Full Article
BioSig Technologies, Inc. (BSGM - Free Report) has made a transformative stride in the field of intracardiac signal visualization with the launch of its subscription model for the PURE EP Platform. This strategic move, while aligning perfectly with the company's vision, caters to the evolving needs of electrophysiologists and cardiology spaces.
The recent agreement with the prestigious Cleveland Clinic marks a significant milestone in this endeavor.
More on the News
BioSig's subscription model for PURE EP provides electrophysiologists and cardiology departments with great flexibility. It allows access to the latest features and the ability to customize the rich suite of PURE EP software capabilities to meet their specific needs. This combination of hardware and software offers real-time, ultra-pure cardiac signal data, opening up new horizons in arrhythmia care and procedures.
BioSig's shift to a subscription-based model reflects a strategic move from a traditional ownership paradigm to a value-centric approach. Gray Fleming, the chief commercial officer of BioSig, emphasized that the subscription model aligns with the company's drive to advance technology boundaries, focusing on signal hygiene, analysis and data application. This shift not only promotes constant innovation but also supports operational expenditure goals by optimizing day-to-day department expenses, freeing medical professionals from the burdens of ownership and maintenance.
Image Source: Zacks Investment Research
Clinical Validation and Collaborative Innovation
The partnership with Cleveland Clinic, a renowned institution in cardiology and heart surgery, further solidifies BioSig's commitment to innovation and clinical validation. The recent research presented at the Heart Rhythm Society 2023 showcased the effectiveness of PURE EP's signal guidance in optimizing ablation procedures. The findings, demonstrating a 66% reduction in procedure time while maintaining accuracy and precision during pulmonary vein isolation, underscore the potential clinical benefits of the platform.
Market Prospect
According to a Polaris Market Research report, the global arrhythmia treatment market was valued at $6.39 billion in 2021. It is poised for robust expansion at a CAGR of 6.8% throughout the forecast period of 2022 to 2030.
Unhealthy dietary habits, notably the surge in junk food/fast food consumption, are triggering a decline in global population health, fostering higher rates of obesity, particularly in developed nations. This escalating obesity epidemic is set to fuel vertical growth. Moreover, the prevalence of risk factors, like smoking, significantly augments the disorder's incidence, propelling the market forward. The market is further driven by a rising prevalence of arrhythmia in Asia, highlighting substantial growth potential across the region. With these factors harmonizing, the global arrhythmia treatment market holds promise for the future.
Price Performance
In the past year, BSGM shares have decreased 48.4% against the industry’s rise of 0.5%.
Haemonetics’ stock has risen 15% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and from $3.96 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 159.5% in the past year against the industry’s decline of 1.4%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 23.6% in the past year against the industry’s fall of 0.5%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model
BioSig Technologies, Inc. (BSGM - Free Report) has made a transformative stride in the field of intracardiac signal visualization with the launch of its subscription model for the PURE EP Platform. This strategic move, while aligning perfectly with the company's vision, caters to the evolving needs of electrophysiologists and cardiology spaces.
The recent agreement with the prestigious Cleveland Clinic marks a significant milestone in this endeavor.
More on the News
BioSig's subscription model for PURE EP provides electrophysiologists and cardiology departments with great flexibility. It allows access to the latest features and the ability to customize the rich suite of PURE EP software capabilities to meet their specific needs. This combination of hardware and software offers real-time, ultra-pure cardiac signal data, opening up new horizons in arrhythmia care and procedures.
BioSig's shift to a subscription-based model reflects a strategic move from a traditional ownership paradigm to a value-centric approach. Gray Fleming, the chief commercial officer of BioSig, emphasized that the subscription model aligns with the company's drive to advance technology boundaries, focusing on signal hygiene, analysis and data application. This shift not only promotes constant innovation but also supports operational expenditure goals by optimizing day-to-day department expenses, freeing medical professionals from the burdens of ownership and maintenance.
Image Source: Zacks Investment Research
Clinical Validation and Collaborative Innovation
The partnership with Cleveland Clinic, a renowned institution in cardiology and heart surgery, further solidifies BioSig's commitment to innovation and clinical validation. The recent research presented at the Heart Rhythm Society 2023 showcased the effectiveness of PURE EP's signal guidance in optimizing ablation procedures. The findings, demonstrating a 66% reduction in procedure time while maintaining accuracy and precision during pulmonary vein isolation, underscore the potential clinical benefits of the platform.
Market Prospect
According to a Polaris Market Research report, the global arrhythmia treatment market was valued at $6.39 billion in 2021. It is poised for robust expansion at a CAGR of 6.8% throughout the forecast period of 2022 to 2030.
Unhealthy dietary habits, notably the surge in junk food/fast food consumption, are triggering a decline in global population health, fostering higher rates of obesity, particularly in developed nations. This escalating obesity epidemic is set to fuel vertical growth. Moreover, the prevalence of risk factors, like smoking, significantly augments the disorder's incidence, propelling the market forward. The market is further driven by a rising prevalence of arrhythmia in Asia, highlighting substantial growth potential across the region. With these factors harmonizing, the global arrhythmia treatment market holds promise for the future.
Price Performance
In the past year, BSGM shares have decreased 48.4% against the industry’s rise of 0.5%.
Zacks Rank and Key Picks
BioSig currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Quanterix (QTRX - Free Report) and SiBone (SIBN - Free Report) . While Haemonetics sports a Zacks Rank #1 (Strong Buy), Quanterix and SiBone each carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 15% in the past year. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and from $3.96 to $4.07 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 19.39%. In the last reported quarter, it posted an earnings surprise of 38.16%.
Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 159.5% in the past year against the industry’s decline of 1.4%.
QTRX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 30.39%. In the last reported quarter, it posted an earnings surprise of 55.56%.
Estimates for SiBone’s2023 loss have narrowed from $1.42 to $1.27 per share in the past 30 days. Shares of the company have increased 23.6% in the past year against the industry’s fall of 0.5%.
SIBN’s earnings beat estimates in all the trailing four quarters, the average surprise being 20.37%. In the last reported quarter, SiBone delivered an earnings surprise of 26.83%.
Disclaimer: This article has been written with the assistance of Generative AI. However, the author has reviewed, revised, supplemented, and rewritten parts of this content to ensure its originality and the precision of the incorporated information.